Stephen Baker is a director of research for global health in the Department of Medicine at the University of Cambridge. His research focusses on studying the mechanisms and epidemiological influences of antimicrobial resistant Gram-negative bacteria. His group used various genomic and laboratory techniques to understand how antimicrobial resistant bacterial emerge and spread and how best they can be combatted through antimicrobials and vaccines. He has published over 300 scientific articles and is a recognized name in global health with a portfolio of work ranging from typhoid fever and other enteric diseases to hospital acquired infections and zoonoses. Stephen’s research combines novel immunological, diagnostic, and computational platforms to address urgent AMR threats. These include monoclonal antibodies (mAbs), delivery of mAbs, machine learning-powered bacterial phenotyping via high-content imaging, molecular diagnostics, offering low-cost, multiplexed RNA detection without amplification, multiplex serosurveillance assays to guide vaccine deployment and monitor AMR exposure in high-burden settings. His work offers a unique advantage through its integration of translational pipelines and regional public health access in Southeast Asia, and directly supports Singapore’s goals in pandemic preparedness, health-tech innovation, and regional biomedical leadership. Stephen’s programme will contribute to building a first-in-human AMR biologics pipeline, establishing Singapore as a launchpad for diagnostics and therapeutics tailored to regional needs, strengthening public–private partnerships and IP development, developing next-generation scientific talent with translational and interdisciplinary expertise. Expansion of a monoclonal antibody discovery platform against Acinetobacter baumannii, Klebsiella pneumoniae, and other Gram-negative AMR pathogens. Using human immune repertoire transgenic mice, his team, in collaboration with Sanofi, generated fully human monoclonal antibodies targeting conserved outer membrane structures of A. baumannii. This approach yielded potent, protective antibodies, demonstrating efficacy in preclinical models and paving the way for novel immunotherapeutics against multidrug-resistant bacteria. This approach can be adopted to target other Gram-negative bacteria.